Home
    Disclaimer
    ← Back to ALD-52
    ALD-52 molecular structure

    ALD-52 Stats & Data

    Psychedelic Research-chemical
    1a-lsd 1a-lad 1-acetyl-lsd Orange sunshine ald52 1alsd
    NPS DataHub
    MW365.48
    FormulaC22H27N3O2
    CAS3270-02-8
    IUPAC(6~{a}~{R},9~{R})-4-acetyl-~{N},~{N}-diethyl-7-methyl-6,6~{a},8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
    SMILESCCN(CC)C(=O)C1CN(C)C2Cc3cn(C(C)=O)c4cccc(C2=C1)c34
    InChIKeyFJOWXGYLIWJFCH-OXQOHEQNSA-N
    2020/5.2 Δ9 10-Ergolene; 2021/5.2 Δ9 10-Ergolene; 2022/5.2 Δ9 10-Ergolene
    Chemical Class Lysergamide
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor partial agonist
    5-HT2C receptor partial agonist
    5-HT1A receptor partial agonist
    D2 receptor agonist (through LSD metabolite)

    Effect Profile

    Curated + 36 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10108.0
    Headspace Depth×3
    10104.0
    Auditory Effects×1
    10104.0
    Body Load / Somatic Effects×1
    109.64.0
    Catalog Erowid BlueLight
    Based on reports from:
    Effect Index Twisted Flesh — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki ALD-52

    Community Effects

    TripSit
    Negative
    dehydration

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    90% ●○○
    Psilocybin
    80% ●○○
    Psilocin
    80% ●○○
    Mescaline
    60% ●○○
    DMT
    80% ●○○
    5-MeO-DMT
    80% ●○○
    2C-B
    60% ●○○
    2C-E
    60% ●○○

    Experience Report Analysis

    Erowid BlueLight
    31 Reports
    2013–2019 Date Range
    29 With Age Data
    28 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 36 experience reports (31 Erowid + 5 Bluelight)

    36 Reports
    52 Effects Detected
    18 Positive
    21 Adverse
    13 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 18

    Color Enhancement 61.3% 70%
    Music Enhancement 61.3% 70%
    Euphoria 54.8% 70%
    Focus Enhancement 47.2% 85%
    Stimulation 44.5% 80%
    Empathy 41.9% 70%
    Body High 38.7% 70%
    Tactile Enhancement 38.7% 70%
    Joy 20.0% 85%
    Silliness 20.0% 80%
    Contentment 20.0% 80%
    Well-Being 20.0% 85%
    Analysis Enhancement 20.0% 75%
    Sociability Enhancement 20.0% 80%
    Gratitude 20.0% 75%
    Awe 20.0% 75%
    Introspection 19.4% 70%
    Creativity Enhancement 9.7% 70%

    Adverse Effects 21

    Anxiety 77.8% 92%
    Confusion 52.8% 80%
    Muscle Spasm 40.0% 88%
    Motor Suppression 40.0% 75%
    Nausea 33.3% 95%
    Thought Loops 25.0% 90%
    Body Load 20.0% 85%
    Social Anxiety 20.0% 85%
    Paranoid Ideation 20.0% 75%
    Delusion 20.0% 85%
    Panic 20.0% 90%
    Fear 20.0% 90%
    Vomiting 20.0% 95%
    Melting/flowing 20.0% 80%
    Anger 20.0% 75%
    Visual Fragmentation 20.0% 70%
    Muscle Tension 13.9% 85%
    Pupil Dilation 12.9% 70%
    Headache 12.9% 70%
    Sweating 9.7% 70%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Common (n=10)
    Visual Distortions 100.0%
    Anxiety 80.0%
    Confusion 70.0%
    Euphoria 60.0%
    Focus Enhancement 60.0%
    Tactile Enhancement 60.0%
    Color Enhancement 40.0%
    Body High 40.0%
    Music Enhancement 40.0%
    Sedation 30.0%
    Auditory Effects 30.0%
    Time Distortion 30.0%
    Empathy 30.0%
    Introspection 30.0%
    Pupil Dilation 20.0%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 31 experience reports.

    Limited tier coverage — most reports fall within the Common range. Effects at other dose levels may not be represented.

    Oral dose range: 100.0–250.0 µg (median 125.0 µg)
    Effect Common (n=10)
    visual distortions
    100%
    anxiety
    80%
    confusion
    70%
    euphoria
    60%
    focus enhancement
    60%
    tactile enhancement
    60%
    color enhancement
    40%
    body high
    40%
    music enhancement
    40%
    sedation
    30%
    auditory effects
    30%
    time distortion
    30%
    empathy
    30%
    introspection
    30%
    pupil dilation
    20%
    nausea
    20%
    appetite suppression
    20%
    thought loops
    20%
    jaw clenching
    20%
    increased heart rate
    20%

    Showing top 20 of 21 effects

    Dosage Distribution

    Dose distribution from experience reports

    Median: 125.0 µg IQR: 100.0–250.0 µg n=12

    Real-World Dose Distribution

    62K Doses

    From 36 individual dose entries

    Oral (n=18)

    Median: 0.15mg 25th: 0.11mg 75th: 0.24mg 90th: 0.27mg
    mg/kg median: 0.002 mg/kg 75th: 0.003

    Sublingual (n=12)

    Median: 0.17mg 25th: 0.12mg 75th: 0.27mg 90th: 0.3mg
    mg/kg median: 0.003 mg/kg 75th: 0.004

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Oral

    Median: 0.002 mg/kg IQR: 0.002–0.003 mg/kg n=12

    Sublingual

    Median: 0.004 mg/kg IQR: 0.001–0.008 mg/kg n=7

    Redose Patterns

    Redosing behavior across 27 reports

    11.1% Redosed
    1.1 Avg Doses
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria ALD-52 is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
    Denmark ALD-52 is not listed as an illegal substance in Denmark as of April 2019, and its chemical class 'lysergamide' is not banned under the Analogue Act (some LSD analogues are, however, prohibited).
    Finland ALD-52 is labeled a controlled psychoactive substance in Finland as of 2014.
    Germany ALD-52 is controlled under the NpSG as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
    Latvia ALD-52 is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
    Poland ALD-52 is a NPS class drug in Poland, making it illegal to possess or distribute.
    Romania ALD-52 is illegal to produce or sell in Romania. It is not included directly in the list of controlled substances, but it is included in an analogue act. However, it is not, as of yet, classified as illegal to use.
    Singapore ALD-52 is a class A controlled drug, and is illegal to traffic, manufacture, import, export, possess, or consume in Singapore as of December 1, 2019, punishable with a minimum of five years' imprisonment and five strokes of the cane.
    Switzerland Since March 2018, ALD-52 is illegal in Switzerland and has been put in the RS 812.121.11.
    United Kingdom On June 10, 2014, the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ALD-52 be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
    United States ALD-52 is unscheduled in the United States. It may be considered an analogue of LSD, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or scientific use could be prosecuted as crimes under the Federal Analogue Act however could be legal for medical and research uses like a research chemical.

    References

    Data Sources

    Cited References

    ← Back to ALD-52